Clinical trials
Diabetic Retinopathy clinical trials
Below are recruiting diabetic retinopathy clinical trials, each written for real people, not researchers. We’re tracking 85 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03403686Recruiting
Study eye treatment target for diabetic retinopathy
This study tests a new approach aimed at improving diabetic eye disease (diabetic retinopathy). It may help by changing inflammation and related processes in the eye, especially in people who have diabetes and eye changes.
Birmingham, AlabamaAges 21–98 - NCT04187443RecruitingPhase 1
Drug MS-553 for diabetic eye swelling with reduced vision
This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.
Changsha, HunanAges 18 years+ - NCT06879834Recruiting
AI software for diabetic eye screening
This study tests an AI platform that checks for diabetic retinopathy, a common eye problem in people with diabetes. It aims to see if the AI can spot signs of damage early, so you can get treatment sooner.
OdesaAges 18–90 - NCT07520045Recruiting
Eye Injections for Diabetic Vision Loss: Two Treatment Comparison
This study compares two injectable medications (faricimab and biosimilar ranibizumab) used to treat diabetic retinopathy, a serious eye condition that can cause vision loss in people with diabetes. The trial will measure how well each medication works and track specific markers in your eye to understand treatment response.
OsijekAges 18 years+ - NCT07586787Recruiting
Early Vitrectomy vs Laser for Early Diabetic Eye Disease
This trial compares two treatments for early diabetic retinopathy—a condition where high blood sugar damages blood vessels in the eye. Researchers want to see if removing fluid from inside the eye (vitrectomy) works better than laser treatment to prevent vision loss.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06269419Recruiting
Diabetes eye disease natural progression study
This study follows people with type 2 diabetes to understand how diabetic retinopathy (an eye disease caused by diabetes) changes over time without treatment. It may help if you have no other eye issues causing new blood vessels and are not planning for certain eye procedures.
Chengdu, SichuanAges 18–75 - NCT07069647Recruiting
AI screening for diabetic eye disease and macular degeneration
This trial tests if an AI tool can help detect diabetic retinopathy and age-related macular degeneration in older adults visiting family medicine or geriatric clinics. It aims to catch these eye conditions early, before they cause vision loss.
TaipeiAges 20 years+ - NCT06817265RecruitingPhase 3
TNTL for diabetic eye disease (non-proliferative)
This study tests if a drug called TNTL can help people with type 2 diabetes who have early-stage diabetic eye disease (non-proliferative diabetic retinopathy) without severe vision loss. It aims to see if the treatment is safe and effective in slowing or improving the condition.
Xuancheng, AnhuiAges 18–75 - NCT06412224RecruitingEarly Phase 1
Testing a new drug for diabetic eye disease after vitrectomy
This trial tests a new medicine, RRG001, given after vitrectomy surgery for severe diabetic eye disease. It aims to see if the drug is safe and helps prevent vision loss.
TianjinAges 20–80 - NCT07235085RecruitingPhase 3
Study of OTX-TKI implant for moderate to severe NPDR
This study tests an eye implant (OTX-TKI) that slowly releases a medicine to slow or stop worsening of non-proliferative diabetic retinopathy (NPDR) — an early form of diabetic eye disease. It's for people with moderately severe to severe NPDR who haven't had significant treatments like laser or injections in that eye.
Hagerstown, MarylandAges 18 years+ - NCT06770933RecruitingPhase 2
VX-01 pill for diabetic eye disease study
This trial tests if an oral medication called VX-01 can help people with diabetic eye disease (non-proliferative diabetic retinopathy) that is moderate to severe but not yet at the most advanced stage. It may be an option if you have type 1 or type 2 diabetes and have not had certain prior eye treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT07236879Recruiting
AI eye test for diabetes patients in primary care
This trial uses an artificial intelligence (AI) system to check for diabetic eye disease (retinopathy) during your regular doctor visit. It aims to detect problems early so you can get treatment sooner.
Porto Alegre, Rio Grande do SulAges 18 years+ - NCT07296952Recruiting
Improving transportation for diabetic retinopathy patients
This study tests a new way to help people with diabetic retinopathy get to their eye appointments. It aims to make transportation easier for patients who have Medicaid insurance.
Chicago, IllinoisAges 18 years+ - NCT05883072Recruiting
Using AI to support care for people with diabetes in Pakistan
This study tests whether AI-generated support can be helpful for adults living with diabetes. You may be asked to participate if you live in Pakistan and can legally consent.
Karachi, SindhAges 18–100 - NCT06478407Recruiting
Diabetic Retinopathy Screening in Tianjin 2024
This trial is a community screening program in Tianjin that checks people with diabetes for diabetic retinopathy. It aims to find early signs of eye damage from diabetes so you can get the right care.
Tianjin, Tianjin MunicipalityAges Any age - NCT06899529Recruiting
Bevacizumab after eye surgery for diabetic retinopathy
This trial tests whether giving bevacizumab (a medicine that slows abnormal blood vessel growth) right after vitrectomy (a surgery to remove blood or scar tissue from the eye) can help people with advanced diabetic eye disease. The goal is to improve vision and reduce the need for more treatments.
Querétaro City, QuerétaroAges 18 years+ - NCT07468058Recruiting
Diabetic eye disease study in Da Nang
This study looks at how common diabetic retinopathy is and what factors increase the risk. It may help find better ways to prevent vision loss in people with diabetes.
Da NangAges 18 years+ - NCT07378956Recruiting
AI eye screening for diabetes patients
This study uses an artificial intelligence (AI) tool to analyze eye images in people with type 2 diabetes. The goal is to see if the AI can help detect early signs of diabetic eye disease, so you can get the right care sooner.
Incheon, Gyeonggi-doAges 19 years+ - NCT04240652Recruiting
Diabetes eye screening and prevention program for eye disease
This program aims to screen people for diabetic eye problems early and help prevent vision loss over time. It may help you if you have type 2 diabetes (or you’ve been invited as a diabetes/non-diabetes participant) and can safely take part in the study activities.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06124586Recruiting
Early angioplasty for diabetic foot ulcers
This trial tests if an early procedure to open blocked leg arteries (angioplasty) helps heal foot ulcers in people with type 2 diabetes. It aims to improve blood flow and prevent amputation.
DüsseldorfAges 18 years+ - NCT07259928RecruitingPhase 2
Testing ANXV for diabetic retinopathy or retinal vein occlusion
This trial tests a new drug called ANXV (Annexin A5) to see if it is safe and can help people with diabetic retinopathy or a recent retinal vein occlusion. The goal is to reduce eye damage and improve vision.
LondonAges 18 years+ - NCT07758582Recruiting
Artificial intelligence for detecting diabetic retinopathy from eye photos
This study tests an AI system that automatically detects signs of diabetic retinopathy from eye photos. It aims to see if the AI can accurately identify these signs to help with early detection.
AlexandroupoliAges 18 years+ - NCT06264427Recruiting
Study of metabolism issues in Greenland
This study looks at the genes and physical traits of people in Greenland with type 2 diabetes or severe obesity. It aims to better understand these conditions to improve care.
Nuuk, SermersooqAges 18 years+ - NCT06787482RecruitingPhase 1/Phase 2
Peptide therapy for retinitis pigmentosa
This trial tests a new peptide therapy for people with retinitis pigmentosa (RP), a genetic eye disease that causes vision loss. The goal is to see if the treatment is safe and can help slow or improve vision loss.
CairoAges Any age
Hear when a new Diabetic Retinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for diabetic retinopathy?
- Yes. Clin2 currently lists 85 recruiting diabetic retinopathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diabetic retinopathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diabetic retinopathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.